According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “
Several other brokerages also recently commented on UROV. ValuEngine raised shares of Urovant Sciences from a hold rating to a buy rating in a research note on Thursday, April 2nd. BidaskClub raised shares of Urovant Sciences from a sell rating to a hold rating in a research note on Wednesday, June 3rd. Finally, HC Wainwright lowered their target price on shares of Urovant Sciences from $33.00 to $28.00 and set a buy rating for the company in a research note on Friday, June 19th.
UROV opened at $10.19 on Friday. The company has a debt-to-equity ratio of 1.83, a current ratio of 1.89 and a quick ratio of 1.89. The company has a market cap of $316.31 million, a price-to-earnings ratio of -2.11 and a beta of 1.45. The firm has a 50 day simple moving average of $10.06 and a 200 day simple moving average of $11.14. Urovant Sciences has a fifty-two week low of $6.55 and a fifty-two week high of $15.98.
Urovant Sciences (NASDAQ:UROV) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($1.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.43). As a group, analysts expect that Urovant Sciences will post -6.88 EPS for the current year.
A number of large investors have recently modified their holdings of UROV. Perceptive Advisors LLC boosted its holdings in shares of Urovant Sciences by 7.1% in the fourth quarter. Perceptive Advisors LLC now owns 2,406,931 shares of the company’s stock valued at $37,331,000 after buying an additional 160,384 shares during the period. FMR LLC boosted its holdings in shares of Urovant Sciences by 28.4% in the first quarter. FMR LLC now owns 1,710,836 shares of the company’s stock valued at $17,194,000 after buying an additional 378,135 shares during the period. Alyeska Investment Group L.P. boosted its holdings in shares of Urovant Sciences by 171.9% in the first quarter. Alyeska Investment Group L.P. now owns 483,168 shares of the company’s stock valued at $4,455,000 after buying an additional 305,437 shares during the period. BlackRock Inc. boosted its holdings in shares of Urovant Sciences by 5.2% in the first quarter. BlackRock Inc. now owns 305,489 shares of the company’s stock valued at $2,817,000 after buying an additional 15,219 shares during the period. Finally, First Manhattan Co. acquired a new position in shares of Urovant Sciences in the first quarter valued at approximately $2,114,000. 23.81% of the stock is owned by hedge funds and other institutional investors.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Story: What is a price target?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.